Trial Profile
Phase II, Open, Single Group, Multicentre Study to Evaluate the Efficacy and Safety of Lanreotide Autogel Administered Every 4 Weeks by Deep Subcutaneous Injection in the Tumour's Growth Stabilization of Patients With Progressive Neuroendocrine Tumours Who Are Not Eligible to be Treated With Either Surgery or Chemotherapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Lanreotide (Primary)
- Indications Carcinoma; Neuroendocrine tumours
- Focus Biomarker; Therapeutic Use
- Sponsors Ipsen
- 21 Jan 2017 Results of pooled analysis (n=378) of 5 clinical trials (NCT00353496, NCT00842348, NCT00774930, NCT00681187 and NCT00326469) presented at the 2017 Gastrointestinal Cancers Symposium
- 30 Nov 2010 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
- 30 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.